Leerink Partnrs Analysts Boost Earnings Estimates for MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at Leerink Partnrs raised their FY2025 earnings estimates for shares of Mirum Pharmaceuticals in a research note issued on Tuesday, November 4th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.54) per share for the year, up from their prior estimate of ($0.70). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals’ Q4 2025 earnings at ($0.18) EPS and FY2026 earnings at $0.82 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. During the same period in the previous year, the firm posted ($0.30) earnings per share. The company’s quarterly revenue was up 47.1% compared to the same quarter last year. Mirum Pharmaceuticals has set its FY 2025 guidance at EPS.

A number of other research analysts have also recently weighed in on MIRM. TD Cowen upgraded Mirum Pharmaceuticals to a “strong-buy” rating in a report on Thursday, September 25th. HC Wainwright upped their target price on shares of Mirum Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald increased their price target on Mirum Pharmaceuticals from $85.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday. Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 26th. Finally, Stifel Nicolaus set a $89.00 price objective on Mirum Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $83.50.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $67.72 on Friday. The company has a market capitalization of $3.48 billion, a PE ratio of -78.74 and a beta of 0.75. Mirum Pharmaceuticals has a twelve month low of $36.88 and a twelve month high of $78.54. The company has a current ratio of 3.31, a quick ratio of 2.97 and a debt-to-equity ratio of 1.06. The business’s 50-day moving average price is $73.07 and its 200 day moving average price is $58.73.

Insider Activity

In other news, CFO Eric Bjerkholt sold 9,578 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $76.01, for a total value of $728,023.78. Following the completion of the sale, the chief financial officer directly owned 39,945 shares in the company, valued at approximately $3,036,219.45. The trade was a 19.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Laura Brege sold 17,000 shares of the firm’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $74.40, for a total value of $1,264,800.00. Following the transaction, the director owned 15,703 shares in the company, valued at $1,168,303.20. This trade represents a 51.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 66,578 shares of company stock worth $4,472,824. 14.36% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MIRM. MCF Advisors LLC lifted its holdings in Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the last quarter. CWM LLC grew its holdings in shares of Mirum Pharmaceuticals by 259.4% during the first quarter. CWM LLC now owns 593 shares of the company’s stock valued at $27,000 after purchasing an additional 428 shares during the last quarter. Comerica Bank lifted its holdings in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Mirum Pharmaceuticals by 34.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after purchasing an additional 243 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its position in Mirum Pharmaceuticals by 46.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after purchasing an additional 351 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.